
Friday, January 20, 2023 11:41:30 AM
do the manufacturing for Gamida.
This was one of the reasons for the FDA delay
in the approval.
Too bad Gamida has had to pay this substantial
amount for the vreach of contract, the positive
point is that the burden is off their shoulders,
and it seems the road to FDA final approval in
coming May is paved smooth.

Liked By
Spread the love. Be the first to like this post!
Recent GMDA News
- Current Report Filing (8-k) • Edgar (US Regulatory) • 03/27/2023 11:16:25 AM
- Gamida Cell Reports Full Year 2022 Financial Results and Provides Company Update • Business Wire • 03/27/2023 11:00:00 AM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 03/22/2023 08:35:41 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 03/20/2023 08:46:51 PM
- Gamida Cell Announces Changes to Board of Directors • Business Wire • 03/20/2023 08:30:00 PM
- Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2022 Financial Results and Webcast • Business Wire • 03/20/2023 12:00:00 PM
- Gamida Cell to Present Corporate Highlights at the Oppenheimer 33rd Annual Healthcare Conference • Business Wire • 03/07/2023 01:00:00 PM
- Amended Statement of Beneficial Ownership (sc 13d/a) • Edgar (US Regulatory) • 03/03/2023 09:03:47 PM
- Data Presented on Gamida Cell’s Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR • Business Wire • 02/18/2023 05:30:00 PM
- Statement of Ownership (sc 13g) • Edgar (US Regulatory) • 02/14/2023 09:10:55 PM
- Amended Statement of Ownership (sc 13g/a) • Edgar (US Regulatory) • 02/09/2023 04:02:40 PM
- Additional Proxy Soliciting Materials (definitive) (defa14a) • Edgar (US Regulatory) • 01/30/2023 12:03:54 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/30/2023 12:01:20 PM
- Notice of Effectiveness (effect) • Edgar (US Regulatory) • 01/23/2023 11:04:06 AM
- Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) • Edgar (US Regulatory) • 01/20/2023 09:32:22 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/19/2023 09:44:26 PM
- Proxy Statement (definitive) (def 14a) • Edgar (US Regulatory) • 01/10/2023 10:13:59 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/09/2023 05:16:06 PM
- Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) • Edgar (US Regulatory) • 12/30/2022 10:17:38 PM
- Analysts’ Top Healthcare Picks: Crispr Therapeutics AG (CRSP), Arcutis Biotherapeutics (ARQT) • TipRanks • 12/12/2022 06:11:45 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 12/12/2022 12:16:53 PM
- Gamida Cell Announces Closing of $25 Million Financing With Highbridge • Business Wire • 12/12/2022 12:00:00 PM
- Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences • Business Wire • 11/23/2022 01:00:00 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 11/22/2022 09:37:38 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 11/22/2022 09:35:07 PM
FEATURED Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer's Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders Conference • Mar 31, 2023 7:07 AM
ILUS Confirms Further Funding Arrangements and Note Settlement • ILUS • Mar 31, 2023 10:21 AM
Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K • SIGY • Mar 31, 2023 10:06 AM
ARway Secures Multiple New SDK Deals to Drive Growth in $44B Indoor Positioning and Navigation Market • ARWYF • Mar 30, 2023 10:30 AM
Nextech3D.ai Enters Asian Market with Major 3D Modeling Deal to Revolutionize E-Commerce • NTAR • Mar 30, 2023 10:00 AM
OMID Posts 2022 Annual Report and Provides Update • OMID • Mar 30, 2023 9:15 AM